USA Elixiria Biotech Inc
Non-opioid Analgesics and Neuroprotectants
Elixiria is an innovative biopharmaceutical company dedicated to delivering groundbreaking medicines to address the critical needs of patients with neurological disorders including chronic pains
Pipeline
Team
Research Associate Scientist in New York Univ. 20 year drug R&D business experiences. Postdoc from Columbia Univ. and PhD. in Biochem. from the Univ. of Texas. Published 2 patents. ~ 30 papers in neuroscience
Morgan Zhang, PhD
CEO, Chairman
Director and Prof. of Anesthesiol., at Univ. of New Mexico. 36 years’ research experience in pain. Published 10 US patents and ~ 200 papers on pain. Responsible for preclinical efficacy studies in pain.
Karin Westlund, PhD
CSO, Director
MBA from Zhejiang University, China
Zhichao Gao
CFO, Director
B. Sc. from Hubei University, China in Biotechnology
Ximing Huang
COO, Director
PPARg agonism as an emerging therapeutic strategy for neurological disorders
Major neurological disorders where PPARg is recognized as a therapeutic target
Neuropathic pains and their unmet needs
Why current PPARg agonists are not ideal in Neurological Disorders
Current PPARg agonists has no therapeutic window in most neurological disorders
A strategy to unlock the therapeutic window
Elixiria’s candidates unlocked the therapeutic window
Limitation of Competitive Non-opioid Painkiller Pipelines
Elixiria unlocked the therapeutic window by ELB00824 for CIPN and many other neurological disorders
Summary of in vivo ELB0824 efficacy in pains and many other neurological disorders
IP and Publications
Elixiria’s approved USA and China patent
Publication for preclinical study on CIPN at Neuropharmacology 2022
Publication for preclinical study on trigeminal pain on Mol Pain 2019
Review on our strategy to unlatch a therap window at Molecules 2020
Site built with Neo - Get yours!